Cargando…
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threonin...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263962/ https://www.ncbi.nlm.nih.gov/pubmed/25563355 http://dx.doi.org/10.3390/jpm4030297 |